
At LabGenius Therapeutics ("LabGenius"), our mission is to discover the next generation of therapeutic antibodies by combining human and machine intelligence. To do this, we’ve pioneered the development of EVA™, state-of-the-art automated platform, enabling the closed-loop discovery of high-performing, non-intuitive antibody designs using proprietary, ML-grade datasets. For our wholly-owned therapeutic pipeline, we’re using our closed-loop discovery engine to establish a pipeline of highly selective T-cell engagers and ADCs for the treatment of solid tumours.
LabGenius has raised >£55M and is backed by top-tier investors, including M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital and Obvious Ventures amongst others. The company is headquartered in London (UK) where we’ve established a cutting-edge antibody engineering facility. The company is staffed by a multidisciplinary team of more than 50 scientists and engineers.
You’ll be a pivotal member of the wet-lab team, serving as the technical lead for antibody binding characterization. This is a high-impact opportunity for a kinetics expert to not only execute assays but to build a world-class antibody binding platform from the ground up.
Your primary mission is to ensure that our ML models are fed with high-resolution, high-quality kinetic data. You won't just be running samples; you will be designing the workflows—using SPR (Surface Plasmon Resonance) and BLI (Biolayer Interferometry)—to transition our discovery pipeline from crude screening to clinical-grade lead optimization.
You’ll be a member of our antibody developability team, where you’ll ensure that the "best" binders also possess the biophysical properties required to become successful therapeutic products. You won't just be looking at how well an antibody binds; you’ll be stress-testing its "fitness" for clinical use, identifying liabilities like aggregation, instability, or poor solubility early in the pipeline.
Whatever your previous experience includes, you’ll inject passion and energy into everything you do. You’ll enjoy multi-disciplinary work, and you’ll have an endless hunger for knowledge, learning, and growth; all the qualities LabGenius Therapeutics celebrates!
Your role at LabGenius Therapeutics will be varied, with clear communication being critical to your day-to-day interactions with the team. Being able to integrate your workflow with other teams, along with the ability to share findings in an articulate manner, will help you to achieve success within this position.
This position is a full time laboratory-based role, on a 12 month fixed term contract.
Design, implement, and "own" our internal antibody binding platform, selecting the best-fit instrumentation (e.g., Biacore, Octet,) to scale our characterization capabilities.
Lead high-resolution kinetic screening campaigns to determine kon, koff, and KD for large panels of antibody candidates.
Execute complex epitope binning and mapping studies to ensure diverse target coverage and support intellectual property filings.
Partner with the Lab Automation team to integrate liquid handling with BLI workflows, moving toward fully autonomous binding assays.
Work closely with our Data Science team to translate raw sensorgrams into clean datasets for ML/AI predictive models, ensuring our in silico scoring is grounded in precise physical measurements.
Design and implement automated biophysical screening assays (e.g., HT-protein stability, solubility, and self-association) using 96- and 384-well formats
Analyse data from high throughput screening and work with our data science team to feed biophysical "wet-lab" data into predictive models (ML/AI) for in silico developability scoring.
QC analyse, interpret and troubleshoot developability experiments working closely with other R&D teams.
Conduct research in a self-directed manner, troubleshooting complex binding profiles (e.g., multi-phasic binding or non-specific interactions) to provide actionable insights to the engineering team.
Keep excellent experimental/data records for cross-functional teamwork and project learnings.
Organise and manage your time effectively, balancing competing priorities based on business goals and the focus of your wider team, to deliver to timelines where others are relying on you.
You have a PhD in protein/antibody engineering, protein biochemistry, or an MSc with 3-5 years of industrial experience with significant wet-lab expertise in protein characterisation techniques. Any relevant biotech or pharma experience is a distinct advantage.
Deep, hands-on mastery of SPR (Biacore/Sierra) or BLI (Octet/Pioneer). You should be an expert in kinetic assay design, including sensor chip selection, immobilization strategies, and regeneration optimization
A proven track record of managing large-scale screening campaigns (hundreds of samples per week) without compromising data integrity.
Proficiency in data analysis software (e.g., Insight Evaluation, Scrubber) and a sophisticated understanding of 1:1 binding models vs. complex interactions.
You have experience in thermostability assays (such as DSF), ELISA-based techniques, dynamic light scattering (DLS), and analytical UPLC techniques (such as SE-HPLC and HIC-HPLC).
You have a deep understanding of antibody structure-function relationships and PTM liabilities.
The ability to generate and implement new ideas, specifically in the context of setting up new lab infrastructure and automated workflows.
You’re comfortable with challenging yourself and acquiring unfamiliar scientific skills and knowledge.
Ability to articulate complex kinetic data to non-experts, including computational biologists and stakeholders.
You have excellent organisational and time management skills, with demonstrated ability to prioritise, define timelines and deliver to these commitments.
You’re self-motivated with a strong desire to make an impact, and bring a positive attitude to everything you do.
Experience in a business context, working as part of a multidisciplinary team.
Experience with high-throughput array-based SPR (e.g., Carterra LSA) or BLI (e.g. Octet RH96)
Experience characterizing non-traditional modalities like bispecifics, VHH, or scaffold proteins, and studying complex binding interactions that go beyond the 1:1 model.
You are familiar with complex LIMS systems for data analysis and data integrity.
You are familiar with open source software and bioinformatics tools to support protein production analysis.
Aside from being part of our brilliant, purpose-driven team, you’ll also enjoy:
Financial 💸
Discretionary performance-linked annual bonus
A generous stock option plan
3x Salary Life Assurance
Income Protection
Health Shield Cash Back Plan on day-to-day health expenses
5% pension, with an additional top up on tax savings from us
Free Will-writing Service
Health 🍏
Private Medical Insurance, including dental and optical (currently with AXA)
Discounted gym membership through either AXA or HealthShield
24/7 access to GP Services
Access to the Cycle to Work scheme: to make your commute cheaper, healthier and a whole lot greener
Time-Off ⏰
25 days annual leave (plus the bank holidays)
1 day paid for moving home
Paid sick leave
Compassionate and emergency leave
Wellbeing 💛
Employee Assistance Programme including access to coaching and CBT sessions
Team-building 🤝
Weekly team lunches through Feedr.
A programme of social events both company-wide and within your own teams
Diversity & Inclusion
We believe that diversity makes for innovative, exceptional teams.
We are an equal opportunity employer and do not discriminate based on gender, race, colour, religion or belief, national origin, age, sexual orientation, marital status, disability, or any other protected class.
If you don't feel like you meet every single requirement of this role, we still want to hear from you! We encourage you to apply, have a discussion with us about the role or others that we may have at LabGenius either now or in the future, together we can build more inclusive workplaces.

LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVA™ is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.